Opendata, web and dolomites

oncNGS SIGNED

NGS diagnostics in 21st century oncology: the best, for all, at all times

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 oncNGS project word cloud

Explore the words cloud of the oncNGS project. It provides you a very rough idea of what is the project "oncNGS" about.

contracted    unacceptable    breaking    procedure    efficient    eight    diagnostics    solid    lowering    hc    rna    oncngs    phases    strategy    innovative    spain    tumour    capacity    affordable    analytical    ibsal    intellectual    medicines    belgium    freedom    valuable    limited    ict    material    clinical    consist    obtain    decision    validation    ijb    germany    medical    dcp    compare    launching    precommercial    market    rights    reporting    equal    pooling    italy    treatments    france    biomedical    competitive    experts    lymphomas    property    unmet    malignancies    outcome    inequities    sc    dna    acc    therapies    biopsies    ngs    buyers    profiling    pan    inca    bcr    liquid    hcl    ico    leads    solution    aquas    interpretation    operate    statistics    six    supplies    perform    suppliers    molecular    commercial    tests    establishment    marker    procurement    lmu    ic    expert    diverse    vhio    patients    thanks    haematologic    entities    cancer    tumours    prototyping    solutions    kit   

Project "oncNGS" data sheet

The following table provides information about the project.

Coordinator
SCIENSANO 

Organization address
address: JULIETTE WYTSMANSTRAAT 14
city: ELSENE
postcode: 1050
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 12˙221˙843 €
 EC max contribution 10˙999˙659 € (90%)
 Programme 1. H2020-EU.3.1.5. (Methods and data)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme PCP
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCIENSANO BE (ELSENE) coordinator 8˙436˙825.00
2    ALLEANZA CONTRO IL CANCRO IT (ROMA) participant 434˙614.00
3    INSTITUT CATALA D'ONCOLOGIA ES (L'HOSPITALET DEL LLOBREGAT) participant 314˙317.00
4    HOSPICES CIVILS DE LYON FR (LYON) participant 300˙375.00
5    INSTITUT JULES BORDET BE (BRUXELLES) participant 300˙375.00
6    INSTITUT CURIE FR (PARIS) participant 300˙111.00
7    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 252˙000.00
8    AGENCIA DE QUALITAT I AVALUACIO SANITARIES DE CATALUNYA ES (BARCELONA) participant 189˙247.00
9    DE CLERCQ & PARTNERS BE (SINT-MARTENS-LATEM) participant 189˙225.00
10    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 89˙367.00
11    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 48˙312.00
12    FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON ES (SORIA) participant 48˙296.00
13    INSTITUT NATIONAL DU CANCER GIP FR (BOULOGNE BILLANCOURT) participant 48˙296.00
14    STICHTING KANKERREGISTER - FONDATION REGISTRE DU CANCER BE (Brussels) participant 48˙296.00

Map

 Project objective

oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in providing: (1) efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of (2) pan-cancer tumour marker analysis kit including NGS analysis integrated with (3) an ICT decision support system including analytical test interpretation and reporting. Thanks to the provided solutions, oncNGS consortium will be able to address their common identified unmet medical needs: (1) Establishment of valuable common tumour profiling strategy allowing to provide equal access to innovative medicines to all; (2) Outcome research analysis after treatments with targeted therapies as diverse testing leads to lowering the pooling capacity of obtained results, needed to obtain large enough sample numbers to perform statistics analyses; (3) Application of such essential testing to all patients, breaking down current unacceptable inequities due to the high costs of current diagnostics tests. oncNGS is a strong consortium composed by eight buyers from five member states (SC and IJB from Belgium, IC and HCL from France, HC and LMU from Germany, ACC from Italy and ICO from Spain) supported by six entities with wide experience in their fields (AQuAS from Spain is expert in precommercial procurement, BCR from Belgium and INCa from France are experts in cancer control, IBSAL and VHIO are experienced in biomedical research in the field of haematologic malignancies and DCP is experts in intellectual property rights and freedom to operate analysis) oncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers through three phases: solution design, prototyping and clinical validation of a limited set of R&D supplies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCNGS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCNGS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

Instand-NGS4P (2020)

Integrated and standardized NGS workflows for Personalised therapy

Read More  

EUCAN-Connect (2019)

A federated FAIR platform enabling large-scale analysis of high-value cohort data connecting Europe and Canada in personalized health

Read More  

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More